Myeloperoxidase and Atherosclerosis
Myeloperoxidase (MPO), a member of the peroxidase family, emerged as a major player in the initiation and propagation of atherosclerotic cardiovascular disease (CVD). Evidence for its role in atherosclerosis include that MPO: a) induces endothelial dysfunction, b) modifies physiologically functional high density lipoprotein (HDL) into “dysfunctional HDL”, c) converts low density lipoprotein (LDL) into more atherogenic modified LDL form, and d) induces endothelial cell death and tissue factor expression involved in plaque vulnerability. Elevated levels of blood MPO are associated with CVD, predict incident risks for myocardial infarction and cardiac death in subjects with acute coronary syndrome, and predict future risk of coronary artery disease (CAD) in healthy individuals. In this article, we review current understandings on the role of MPO in pathophysiological processes involved in atherosclerosis and CVD.
KeywordsMyeloperoxidase Atherosclerosis Cardiovascular disease Coronary artery disease High density lipoproteins Low density lipoproteins Niacin Statins Inflammation Apolipoprotein AI Neutrophils
This work has been supported, in part, by Veterans Affairs Merit Review Programs and Southern California Institute for Research and Education.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 7.• Tang WH, Katz R, Brennan ML, et al. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol. 2009;103:1269–74. This is a case–control study showing serum MPO levels are associated with the risk of future development of coronary artery disease in healthy subjects.PubMedCrossRefGoogle Scholar
- 8.Wong ND, Gransar H, Narula J, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. J Am Coll Cardiol Img. 2009;2:1093–9.Google Scholar
- 29.Hazen SL, Gaut JP, Crowley JR, et al. Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino acid derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions, and advanced atherosclerotic lesions. Biochem J. 2000;352:693–9.PubMedCrossRefGoogle Scholar
- 31.Landmesser U, Hornig B, Drexler H. Endothelial function. A critical determinant in atherosclerosis. Circulation. 2004;109(Suppl I):II-27–II-33.Google Scholar
- 39.Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoproteins, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 1979;76:333–7.Google Scholar
- 45.Ansell BJ, Navab M, Hama S, et al. Inflammatory/anti-inflammatory properties of high density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6.PubMedCrossRefGoogle Scholar
- 54.Sugiyama S, Kugiyama K, Aikawa M, et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: Involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol. 2004;24:1309–14.PubMedCrossRefGoogle Scholar
- 56.Malle E, Furtmuller PG, Sattler W, et al. Myeloperoxidase: a target for drug development? Brit J Pharmacol. 2007;1–17.Google Scholar